OKYO Pharma Limited Overview
Pro stress-test →OKYO Pharma is a UK-based clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory eye diseases and ocular pain. The company's lead candidate, urcosimod, is advancing through Phase II trials for dry eye disease and neuropathic corneal pain, addressing significant unmet medical needs affecting hundreds of millions of patients globally.
Strategic Profile
Pro stress-test →OKYO leverages its expertise in G protein-coupled receptor (GPCR) biology with a pipeline targeting two large indications: neuropathic corneal pain (NCP), for which it received first FDA IND clearance, and dry eye disease. The company recently raised $20 million (February 2026) to fund Phase 2b/3 trials, demonstrating investor confidence in its clinical progress and commercial potential.
Competitive Landscape
Pro stress-test →OKYO competes in the ophthalmology therapeutics space against larger pharma players developing dry eye and ocular pain treatments. Key competitive advantage stems from its novel GPCR target (chemerin receptor agonist) and first-mover FDA status in NCP. Direct competitors include Allergan/AbbVie (eye disease portfolio) and other clinical-stage biotech firms, though OKYO's specific mechanism differentiates its therapeutic approach.
Industry Context
OKYO Pharma Limited operates in Biopharmaceutical - Ophthalmology/Eye Diseases.
Key facts
Founded: 2007 · Headquarters: London, United Kingdom